Financial Survey: IDEAYA Biosciences (IDYA) versus Its Rivals

IDEAYA Biosciences (NASDAQ:IDYA) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare IDEAYA Biosciences to related businesses based on the strength of its risk, profitability, earnings, institutional ownership, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for IDEAYA Biosciences and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1	1	13	0	2.80
IDEAYA Biosciences Competitors	9869	15284	45613	1598	2.54

IDEAYA Biosciences currently has a consensus target price of $49.55, indicating a potential upside of 57.34%. As a group, “Biotechnology” companies have a potential upside of 124.71%. Given IDEAYA Biosciences’ rivals higher probable upside, analysts plainly believe IDEAYA Biosciences has less favorable growth aspects than its rivals.

Institutional and Insider Ownership

98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 4.7% of IDEAYA Biosciences shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares IDEAYA Biosciences and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
IDEAYA Biosciences	$218.71 million	-$113.70 million	-7.01
IDEAYA Biosciences Competitors	$700.54 million	$9.44 million	-18.96

IDEAYA Biosciences’ rivals have higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

IDEAYA Biosciences has a beta of 0.08, suggesting that its stock price is 92% less volatile than the S&P 500. Comparatively, IDEAYA Biosciences’ rivals have a beta of -1.84, suggesting that their average stock price is 284% less volatile than the S&P 500.

Profitability

This table compares IDEAYA Biosciences and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	-1,157.18%	-39.78%	-36.25%
IDEAYA Biosciences Competitors	-12,323.33%	-195.91%	-30.60%

About IDEAYA Biosciences

IDEAYA Biosciences, Inc. is a precision oncology company focused on discovering and developing targeted medicines for patients with cancer. Its research uses insights into tumor genetics and synthetic lethality—the idea that certain genetic changes can make cancer cells especially vulnerable to blocking a related biological pathway—to identify potential treatment targets. The company’s investigational pipeline includes small-molecule therapies aimed at specific cancer-related targets. Programs have included darovasertib, a protein kinase C inhibitor being studied in uveal melanoma, and IDE397, a MAT2A inhibitor being developed for tumors with particular genetic alterations.